Telemonitoring of Treatment Effects in Connective Tissue Disease-associated Interstitial Lung Disease (TEL-CTD-ILD)

Key facts

Sponsor

Medical University of Lodz

Principal Investigator

Wojciech Piotrowski, Assoc. Prof.

Department of Pneumology and Allergy, Medical University of Lodz

Intervention

Telemonitoring(other)

Enrollment

60 target

Eligibility

18 years · All sexes

Timeline

2020 – 2022

Study locations (1)

• Department of Pneumology and Allergy, Medical University of Lodz, Lodz, Lodz Province, Poland

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Secondary interstitial lung disease in childhood and adulthood associated with a connective tissue disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2, PHASE3NCT06674148
  A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)
  Huilan Zhang
• RECRUITINGPHASE1, PHASE2NCT06574581
  ADSCs Therapy in Patients With CTD-ILD
  China Medical University Hospital
• ACTIVE NOT RECRUITINGNCT05503030
  Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients
  Boehringer Ingelheim

See all trials for Secondary interstitial lung disease in childhood and adulthood associated with a connective tissue disease →